Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

The persistent coronavirus disease 2019 (COVID-19), characterized by severe respiratory
syndrome, is caused by coronavirus 2 (SARS-CoV-2), and it poses a major threat to public …

The new vaccines against SARS-CoV-2 are novel in terms of specificity, their wide
dissemination across the global population and the inclusion of newly licensed mRNA …

While the immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID‐
19) has been characterized in several well-conducted clinical trials, real-world evidence …

Covid-19 Vaccines — Immunity, Variants, Boosters | NEJM Skip to main content NEJM Group
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician …

At the end of 2019, a new disease recognized such as severe acute respiratory syndrome
(SARS), was reported in Wuhan, China. This disease was caused by an unknown SARS …

In an effort to control the COVID-19 pandemic, large-scale vaccination is being implemented
in various countries using anti-SARS-CoV-2 vaccines based on mRNAs, adenovirus vectors …

Initial optimism regarding the development of COVID-19 vaccines has been tempered by the
emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the …